DAX22.957 +1,4%Est505.649 +1,2%MSCI World4.343 -0,1%Top 10 Crypto9,1500 +1,1%Nas21.930 +0,8%Bitcoin61.257 +0,8%Euro1,1561 -0,5%Öl103,2 +3,3%Gold4.504 +0,7%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 SAP 716460 Siemens Energy ENER6Y DroneShield A2DMAA NVIDIA 918422 Lufthansa 823212 BASF BASF11 Deutsche Telekom 555750 Microsoft 870747 Allianz 840400 Volkswagen (VW) vz. 766403 Vonovia A1ML7J Deutsche Bank 514000 Infineon 623100 Mercedes-Benz Group (ex Daimler) 710000
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Hoffen auf 15-Punkte-Plan für Ende des Iran-Krieges: DAX letztlich stark -- US-Börsen höher -- Tesla, BioNTech, Commerzbank, Rüstungsaktien, Merck & Co., Novo Nordisk, GameStop, BASF, VW im Fokus
Top News
Beyond Meat-Aktie im Fokus: Fleischersatzhersteller verschiebt überraschend Bilanzveröffentlichung Beyond Meat-Aktie im Fokus: Fleischersatzhersteller verschiebt überraschend Bilanzveröffentlichung
SpaceX-Aktie bald an der Börse: Musk will mit Börsengang 75 Milliarden Dollar einsammeln SpaceX-Aktie bald an der Börse: Musk will mit Börsengang 75 Milliarden Dollar einsammeln
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Novavax Aktie

Kaufen
Verkaufen
Novavax Aktien-Sparplan
8,04 EUR +0,02 EUR +0,19 %
STU
9,34 USD +0,07 USD +0,70 %
BTT
finanzen.net zero
Novavax jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.1,30 Mrd. EUR

KGV2,64Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA2PKMZ

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS6700024010

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolNVAX

Novavax Aktien News

DatumMeistgelesen
PR NewswireNovavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
PR NewswireNovavax to Participate in Jefferies London Healthcare Conference
PR NewswireNovavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Wer­bungNovavax-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireNovavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
PR NewswireNovavax to Report Third Quarter 2025 Financial Results on November 6, 2025
PR NewswireNovavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
PR NewswireNovavax Continues to Deliver on Sanofi Partnership, Completing Nuvaxovid® EU Marketing Authorization Transfer and Triggering $25 Million Milestone Payment
PR NewswireNovavax Announces Progress on Sanofi Agreement
PR NewswireNuvaxovid® Now Approved in Japan Triggering Takeda Milestone Payment
PR NewswireNovavax to Participate in the Cantor Global Healthcare Conference
PR NewswireNovavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.
PR NewswireNovavax Reports Second Quarter 2025 Financial Results and Operational Highlights
PR NewswireNovavax to Report Second Quarter 2025 Financial Results on August 6, 2025
PR NewswireNovavax's H5N1 Vaccine Candidate Demonstrates Immunogenicity in Preclinical Study
PR NewswireNovavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial
PR NewswireNovavax to Participate in Upcoming Investor Conferences
PR NewswireU.S. FDA Approves BLA for Novavax's COVID-19 Vaccine
PR NewswireNovavax Reports First Quarter 2025 Financial Results and Operational Highlights
PR NewswireNovavax to Participate in BofA Securities 2025 Health Care Conference
PR NewswireNovavax Announces Significantly Improved Terms for Collaboration and License Agreement with Takeda for Nuvaxovid® in Japan
PR NewswireNovavax to Report First Quarter 2025 Financial Results on May 8, 2025
PR NewswireNovavax Appoints Charles Newton to Board of Directors
PR NewswireSHIELD-Utah Study Shows Novavax's COVID-19 Vaccine Induces Lower Reactogenicity Symptoms Compared to mRNA
PR NewswireNovavax Announces Changes to Board of Directors
PR NewswireNovavax to Participate in Upcoming March Investor Conferences
PR NewswireNovavax Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
PR NewswireNovavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights on February 27, 2025
PR NewswireNovavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone
PR NewswireNovavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza
PR NewswireNovavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million
PR NewswireNovavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(c)(4)
PR NewswireNovavax to Participate in Jefferies London Healthcare Conference
PR NewswireNovavax Reports Third Quarter 2024 Financial Results and Operational Highlights
PR NewswireU.S. FDA Removes Clinical Hold on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
PR NewswireNovavax to Host Conference Call to Discuss Third Quarter 2024 Financial Results and Operational Highlights on November 12, 2024
PR NewswireÅsa Manelius Named Managing Director of Novavax AB Site
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX
PR NewswireNVAX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Novavax, Inc. and Encourages Investors to Contact the Firm
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAX

Novavax News

Novavax News: auf dieser Seite finden Sie alle Novavax News und Nachrichten zur Novavax Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Novavax News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Novavax News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.